CoChat

Quality of Life in Patients Suffering from Active Exudative Age-Related Macular Degeneration: The EQUADE Study

Open access

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Purpose: Age-related macular degeneration (AMD) is the main cause of visual loss in the elderly population. With the use of anti-vascular endothelial growth factor, the visual outcomes of exudative AMD patients have been improved. This study was aimed at assessing the quality of life (QoL) of exudative AMD patients treated with ranibizumab and at determining its drivers in a real-life setting. Methods: We performed a national, cross-sectional, observational survey based on questionnaires sent to members of French associations relative to AMD between December 2012 and March 2013. Patients suffering from exudative AMD with at least one intravitreal injection of ranibizumab within the last 6 months were included. Demographics, AMD characteristics, visual acuity (VA) and past and ongoing treatments were collected. The 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) was self-administered. A multivariate model was used to identify QoL drivers. Results: 416 questionnaires fulfilled the complete criteria for both QoL and cost analyses. The mean age of exudative AMD patients was 78.0 years and bilateral involvement was reported in 60.4%. The overall mean QoL score was 53.4. Mental health, driving and role difficulties were the most widely affected domains. After bivariate analyses, long-term illness status, worse VA and higher number of unpaid aids were associated with worse QoL, with odds ratios of 2.4, 5.2 and 11.6, respectively. The mean cost per year and per patient was 1,741 EUR. The main components of costs were aids and services and the purchase of visual equipment. Conclusions: The main predictors of QoL in exudative AMD patients treated with ranibizumab are VA outcomes, home healthcare and social services provided to the patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000433448

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 2 Composite QoL NEI-VFQ-25 score per domain and per category.
Fig. 2 Composite QoL NEI-VFQ-25 score per domain and per category.CC-BY-NC-ND · From the PDF
Fig. 3 Use of different resources.
Fig. 3 Use of different resources.CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 40

Metadata

Authors
Matamoros, E., Maurel, F., Léon, N., Solomiac, A., Bardoulat, I., Joubert, M., Hermans, M., Moser, E., Le Picard, S., Souied, E. H., & Leveziel, N.
Affiliations
  • Centre Hospitalier Universitaire de Poitiers (FR)
  • IQVIA (United States) (US)
  • Retina France (FR)
  • Université Paris-Est Créteil (FR)
  • Université de Poitiers (FR)
Venue
Ophthalmologica
Publisher
S. Karger AG
Published
2015
Volume
234
Issue
3
Pages
151-159
ISSN
  • 0030-3755 (ISSN-L)
  • 1423-0267
OpenAlex
W1873618078
Cited by
40
References
24
Citations by year
2026: 3 · 2025: 4 · 2023: 4 · 2022: 4 · 2021: 6 · 2020: 7 · 2019: 1 · 2018: 6 · 2017: 2 · 2016: 2
FWCI
3.20
Type
journal article
Language
en
Open access
Licence
Locations
  • Ophthalmologica (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Retina France
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
  • Health Sciences › Medicine › Ophthalmology › Ophthalmology and Visual Impairment Studies
Keywords
neovascular age-related macular degeneration, quality of life, ranibizumab, anti-VEGF therapy, visual acuity, NEI VFQ-25, mental health, driving impairment, chronic disease, home health care, social services, cost of care, visual aids, elderly patients
MeSH terms
Ranibizumab, Aged, Aged, 80 and over, Cross-Sectional Studies, Exudates and Transudates, Female, Humans, Male, Middle Aged, Quality of Life, Surveys and Questionnaires, Visual Acuity, Cost of Illness, Sickness Impact Profile, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Wet Macular Degeneration, Intravitreal Injections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Quality of Life in Patients Suffering from Active Exudative Age-Related Macular Degeneration: The EQUADE Study. https://app.cochat.ai/papers/10.1159/000433448
The paper
Matamoros, E., Maurel, F., Léon, N., Solomiac, A., Bardoulat, I., Joubert, M., Hermans, M., Moser, E., Le Picard, S., Souied, E. H., & Leveziel, N. (2015). Quality of Life in Patients Suffering from Active Exudative Age-Related Macular Degeneration: The EQUADE Study. Ophthalmologica. https://doi.org/10.1159/000433448

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.